Galileo Biotech
Multinational biopharmaceutical company focused on discovery and development of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates for oncology and other unmet medical needs. Operates R&D laboratories and a GMP-certified manufacturing facility (Rio de Janeiro) and maintains an extensive preclinical pipeline with planned clinical entries.
Industries
Nr. of Employees
medium (51-250)
Galileo Biotech
Products
Extensive preclinical portfolio of therapeutic antibody assets
A diversified preclinical pipeline of monoclonal antibodies, bispecifics and ADCs targeting multiple oncology indications; multiple assets expected to enter clinical trials.
ELISA kits for detecting anti-SARS-CoV-2 antibodies
ELISA kits for detecting anti-SARS-CoV-2 antibodies (COVID-19), offering choices for diagnosing anti-IgM, IgG and IgM + IgG antibodies.
Extensive preclinical portfolio of therapeutic antibody assets
A diversified preclinical pipeline of monoclonal antibodies, bispecifics and ADCs targeting multiple oncology indications; multiple assets expected to enter clinical trials.
ELISA kits for detecting anti-SARS-CoV-2 antibodies
ELISA kits for detecting anti-SARS-CoV-2 antibodies (COVID-19), offering choices for diagnosing anti-IgM, IgG and IgM + IgG antibodies.
Services
End-to-end discovery and preclinical development capabilities for therapeutic antibodies (target ID, antibody generation, characterization, lead optimization and preclinical candidate selection).
GMP-certified development and manufacturing facilities to support scale-up and production for clinical-enabling batches and diagnostic kit manufacturing.
Development and production of immunochemical diagnostic kits and related assays under certified processes.
Activities to prepare selected assets for regulatory interactions and clinical trial initiation (pre-IND work and clinical-enabling studies).
End-to-end discovery and preclinical development capabilities for therapeutic antibodies (target ID, antibody generation, characterization, lead optimization and preclinical candidate selection).
GMP-certified development and manufacturing facilities to support scale-up and production for clinical-enabling batches and diagnostic kit manufacturing.
Development and production of immunochemical diagnostic kits and related assays under certified processes.
Activities to prepare selected assets for regulatory interactions and clinical trial initiation (pre-IND work and clinical-enabling studies).
Expertise Areas
- Monoclonal antibody discovery and preclinical development
- Antibody-drug conjugate (ADC) development
- Bispecific antibody engineering
- High-throughput target identification and screening
Key Technologies
- Monoclonal antibodies (mAbs)
- Antibody-drug conjugates (ADCs)
- Bispecific antibodies
- High-throughput unbiased screening
News & Updates
Completed acquisition by Antharis Therapeutics; transaction included Galileo's state-of-the-art R&D laboratory and GMP-certified development and manufacturing facility (Aug 23, 2023).
Announcement of a successful Series A financing round that supported growth of the combined entity and pipeline expansion.
Site described as the first in Brazil certified to perform the full workflow of research, development and manufacture for immunochemical diagnostic products.
Completed acquisition by Antharis Therapeutics; transaction included Galileo's state-of-the-art R&D laboratory and GMP-certified development and manufacturing facility (Aug 23, 2023).
Announcement of a successful Series A financing round that supported growth of the combined entity and pipeline expansion.
Site described as the first in Brazil certified to perform the full workflow of research, development and manufacture for immunochemical diagnostic products.